Dr Colin Miles is Head of the Strategy and team leader for the Industrial Biotechnology and Bioenergy sector at BBSRC. His current role is to lead a team in BBSRC to help increase the capacity and capability of the UK academic base in research, training and knowledge exchange activities in UK industrial biotechnology and bioenergy research.
David co-founded Iksuda Therapeutics (formerly Glythera) in 2012, refocusing it into an Antibody Drug Conjugate development company underpinned by its proprietary technology platforms. Prior to Iksuda, David led Actavis’s biosimilar programmes (now Allergan) and started his industrial career developing expression systems with Cobra Biomanufacturing before moving to Eden Biodesign Ltd where he led its Process Development capabilities.
Simon is Head of Commercialisation at the John Innes Centre (JIC). Prior to joining JIC, Simon cofounded, built, and managed early-stage, venture capital-backed biotechnology innovation businesses most recently as a CEO. These businesses include: Chalante (animal health), AgriMetis (crop protection), ZuvaChem (industrial biotech), Arginetix (human health) all incubated by Acidophil and Stell (xenotransplantation). He has worked in the US and UK and is a citizen of both. He is an inventor on issued patents and author of peer-reviewed publications. He began his biotech career after postdoctoral research at the UCSD following graduate and postdoctoral work with at the University of Cambridge